Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer.
about
Impact of hormone receptor status and distant recurrence-free interval on survival benefits from trastuzumab in HER2-positive metastatic breast cancer.Weekly taxane-anthracycline combination regimen versus tri-weekly anthracycline-based regimen for the treatment of locally advanced breast cancer: a randomized controlled trial.
P2860
Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Hormonal therapy might be a be ...... ive, metastatic breast cancer.
@en
type
label
Hormonal therapy might be a be ...... ive, metastatic breast cancer.
@en
prefLabel
Hormonal therapy might be a be ...... ive, metastatic breast cancer.
@en
P2093
P2860
P1476
Hormonal therapy might be a be ...... ive, metastatic breast cancer.
@en
P2093
Bing-He Xu
Jia-Yu Wang
Ruo-Xi Hong
Xue-Lian Chen
P2860
P2888
P356
10.1186/S40880-016-0101-7
P577
2016-04-25T00:00:00Z
P6179
1020584918